| ²é¿´: 705 | »Ø¸´: 3 | |||
zsm0507½ð³æ (СÓÐÃûÆø)
|
[½»Á÷]
EMEAÖеÄthe granting of a product specific waiver for ¡£¡£¡£¡£¡££¿Ôõô½âÊÍ ÒÑÓÐ1È˲ÎÓë
|
|
¹ØÓÚÅ·ÃËEMEAÖÐon the granting of a product specific waiver for rosuvastatin / ezetimibe (EMEA-001278-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council£¬Õâ¾ä»°ÔõôÀí½â£¬ÊÇ˵ rosuvastatin / ezetimibe×¼ÐíÉÏÊÐÁËÂÁíÍâagreeing paediatric investigation plans (PIPs) forthe following medicinesÖеģ¬PIPSÔõôÀí½â£¿the granting of a product specific waiver for ¡£¡£¡£¡£¡££¿Ôõô½âÊÍ£¿×¼ÐíÉÏÊУ¿ |
» ²ÂÄãϲ»¶
²Î±ÈÖÆ¼Á£¬×Ô¼º×öµÄPKÊý¾ÝÓëIF×ÊÁϱ¨µÀµÄÊý¾ÝÏà²îºÜ´ó
ÒѾÓÐ2È˻ظ´
ÆíÇóÖб¾×Ó
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ298È˻ظ´
ÄÔ¹£ÔõôÖÎÁÆ
ÒѾÓÐ3È˻ظ´
ÄÔ¹£ÔõôÖÎÁÆ
ÒѾÓÐ0È˻ظ´
¸÷λ´óÀУ¬H¿ÚÃæÉÏʲôʱºò»áÆÀ£¿£¿£¿
ÒѾÓÐ30È˻ظ´
ÉúÎï×éÖ¯ÖÐÓÐÄ¿±ê·ÖÎöÎרÊôÐÔÔõô×ö
ÒѾÓÐ0È˻ظ´
2026Äêɽ¶«´óѧº£ÑóѧԺÉúÎïÓëÒ½Ò©²©Ê¿ÕÐÉú-Àîϼ¿ÎÌâ×é
ÒѾÓÐ0È˻ظ´
²©Ê¿Ñо¿ÉúÕÐÉú
ÒѾÓÐ0È˻ظ´
Ò©Àíѧ¡¢ÁÙ´²Ò©Ñ§·½Ïò µ÷¼Á
ÒѾÓÐ1È˻ظ´
zsm0507
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 878.3
- É¢½ð: 110
- ºì»¨: 3
- Ìû×Ó: 284
- ÔÚÏß: 156.6Сʱ
- ³æºÅ: 823620
- ×¢²á: 2009-08-07
- ÐÔ±ð: GG
- רҵ: µ°°×ÖÊ×éѧ
2Â¥2012-10-30 10:36:20
ÒÀÈ»Î人ÄÐÉú
Òø³æ (ÕýʽдÊÖ)
- Ó¦Öú: 58 (³õÖÐÉú)
- ½ð±Ò: 220.7
- É¢½ð: 88
- ºì»¨: 8
- Ìû×Ó: 443
- ÔÚÏß: 105.2Сʱ
- ³æºÅ: 2035881
- ×¢²á: 2012-09-28
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É

3Â¥2018-04-12 17:06:00
ÒÀÈ»Î人ÄÐÉú
Òø³æ (ÕýʽдÊÖ)
- Ó¦Öú: 58 (³õÖÐÉú)
- ½ð±Ò: 220.7
- É¢½ð: 88
- ºì»¨: 8
- Ìû×Ó: 443
- ÔÚÏß: 105.2Сʱ
- ³æºÅ: 2035881
- ×¢²á: 2012-09-28
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É

4Â¥2018-04-12 17:11:09













»Ø¸´´ËÂ¥
40